Blastocystis: how do specific diets and human gut microbiota affect its development and pathogenicity?

M. Lepczyńska1 · J. Białkowska2 · E. Dzika1 · K. Piskorz-Ogórek3,4 · J. Korycińska1

Received: 23 January 2017 / Accepted: 8 March 2017 / Published online: 22 March 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract Blastocystis is an enteric parasite that inhabits the gastrointestinal tract of humans and many animals. This emerging parasite has a worldwide distribution. It is often identified as the most common eukaryotic organism reported in human fecal samples. This parasite is recognized and diagnosed more often than ever before. Furthermore, some strains develop resistance against currently recommended drugs, such as metronidazole; therefore, the use of natural remedies or special diets has many positive aspects that may address this problem. The goal of this review is to compare natural treatments and various diets against the efficacy of drugs, and describe their influence on the composition of the gut microbiota, which affects Blastocystis growth and the occurrence of symptoms. This article reviews important work in the literature, including the classification, life cycle, epidemiology, pathogenesis, pathogenicity, genetics, biology, and treatment of Blastocystis. It also includes a review of the current knowledge about human gut microbiota and various diets proposed for Blastocystis eradication. The literature has revealed that garlic, ginger, some medical plants, and many spices contain the most effective organic compounds for parasite eradication. They work by inhibiting parasitic enzymes and nucleic acids, as well as by inhibiting protein synthesis. The efficacy of any specific organic compound depends on the Blastocystis subtype, and, consequently, on its immunity to treatment. In conclusion, the article discusses the findings that human gut microbiota composition triggers important mechanisms at the molecular level, and, thus, has a crucial influence on the parasitic pathogenicity.

Meet Blastocystis sp.: classification and life cycle

Blastocystis is a unicellular protist present throughout the world in the intestines of both healthy and symptomatic humans and animals [1]. Its pathogenic potential is still controversial [2–5]. For many years, it has been suggested that Blastocystis is a commensal organism living in the human intestine. Originally, the parasite was considered to be a harmless yeast until the 1970s, when evidence showed that Blastocystis was actually a protist [6], belonging to the Stramenopiles line of eukaryotic organisms. In 2009, Irikov et al. [7] proposed to place this organism in a separate sixth kingdom named “Chromista”. Until recently, the taxonomy of Blastocystis was based on the host from which it was isolated (B. hominis from humans, B. ratti from rats, etc.). Modern phylogenetic studies have identified a lack of host specificity for B. hominis and B. ratti, and, therefore, have proposed to summarize the name as “Blastocystis species”, with different ribosomal lineages classified into specific subtypes [8, 9].

Morphologically indistinguishable phylogenetic inferences from small subunit rDNA (SSU rRNA) gene sequence analyses revealed considerable genetic divergence among Blastocystis isolated from humans and animals, with a total of 17 subtypes being identified so far [10]. The majority of
human *Blastocystis* carriage is attributable to ST3 [11, 12], appearing quite rarely in non-primate hosts, suggesting that ST3 may be the only subtype (ST) of human/primate origin [13]. Several STs of supposed animal origin are zoonotic, with the ability to infect humans at different frequencies. Therefore, a higher risk of *Blastocystis* infection has been shown in people living in rural areas and/or with close animal contact [14]. Phylogenetic trees comparing *Blastocystis* SSU rDNA sequences have been developed by many researchers in many countries [11, 15, 16]. The trees are mostly created using the neighbor-joining method (with the maximum composite likelihood model) based on either complete SSU rRNA genes or the hypervariable region at the 5'-end of the SSU rRNA gene. Relationships among *Blastocystis* subtypes occurring in humans have been analyzed and groups of STs were named as clades. One clade consists of STs 1, 2, and 5 (the closest relation between ST1 and ST2); another clade consists of STs 3, 4, and 8 (the closest relation between ST3 and ST8). A third clade consists of STs 6, 7, and 9 (where the closest relation is between STs 6 and 9) [8, 11].

The parasite has been known since the early 1900s [1], but only in the last decade has the biology and pathogenicity of this parasite undergone more intensive studies. However, the lack of standardization in detection techniques and methods for molecular characterization has led to confusion and misinterpretation of the data. A number of studies suggested a linkage between *Blastocystis* and gastrointestinal disorders, skin symptoms, and many other problems. Recent epidemiological data demonstrate the association of *Blastocystis* with a variety of disorders [1, 17], such as diarrhea, abdominal pain, fatigue, constipation, flatulence, chronic gastrointestinal illnesses (irritable bowel syndrome, IBS), and skin rash or urticaria [18, 19]. *Blastocystis* has been found in both patients with gastrointestinal symptoms and asymptomatic individuals [20, 21]. According to a number of studies, the life cycle of *Blastocystis* and its pathogenic aspects are still unclear.

*Blastocystis* infects at least 5–15% of individuals in developed countries and 50–100% of individuals in developing countries [22, 23]. The difference can be partly explained by poor hygiene practices and consumption of contaminated water or food in developing countries [24]. The fecal–oral route is considered to be the main mode of transmission. Controversy regarding the commensal or pathogenic nature of the infection has not changed for decades. Many case reports and epidemiological and microbiological studies support a pathogenic role of *Blastocystis* in causing intestinal inflammation and urticarial symptoms [25], while there are many reports on asymptomatic colonization by *Blastocystis* [26, 27]. Other aspects, including mode of transmission, pathogenicity, life cycle, and molecular biology, remain largely unclear.

The prevalence of *Blastocystis* infection is higher than that of other intestinal parasites, such as *Giardia*, *Entamoeba*, or *Cryptosporidium* [4]. In immunocompromised individuals, such as those with human immunodeficiency virus (HIV) infection, the prevalence of *Blastocystis* is between 30 and 38% in developed countries [28, 29]. It is suggested that *Blastocystis* is linked with diarrhea in immunocompromised hosts, such as HIV-infected persons, and nutrition status may be one of the important risk factors associated with co-infections [3]. Children and the elderly appear to be highly susceptible to *Blastocystis* infection [30, 31], while other researchers have suggested that people between 30 and 50 years of age are most prone to being infected by *Blastocystis* [32–34].

Six different morphological forms of the parasite have been reported (vacuolar, granular, amoeboid, avacuolar, multivacuolar, and cystic), with the cyst being the infective stage and the amoeboid form supposedly playing a more active role in the development of clinical manifestations [35]. The vacuolar form is most commonly observed in both laboratory culture and stool samples [36, 37].

The life cycle and transmission of the parasite are still under intensive investigation. Two types of reproduction have been described: asexual reproduction by binary fission and sexual reproduction by autogamy to form a primary cyst [3, 38], which is the only transmissible form of *Blastocystis* [39]. After getting into the intestinal lumen, the cysts first develop into the vacuolar form. In humans, vacuolar forms divide by binary fission and may develop into amoeboid, multivacuolar, or granular forms, before they become pre-cyst [9]. Vacuolar forms undergo encystation in the host intestine, while intermediate cyst forms may be surrounded by a thick fibrillar layer that is subsequently lost during passage into the external environment to infect other individuals. The pre-cyst may also develop into the thin-wall cyst and lead to autoinfection of the host [9]. Information about the transformation from the amoeboid to the vacuolar form and from the vacuolar to the cyst form is lacking. *Blastocystis* is a strict anaerobe and a common inhabitant of the human gastrointestinal tract, as well as other mammals. Many reports suggest that humans are potentially infected by five or more subtypes of *Blastocystis* [40], and that certain animals represent reservoirs for transmission to humans [1].

**Genetic diversity and pathogenicity of *Blastocystis* sp.**

Based on SSU rDNA analysis, at least 17 different STs of *Blastocystis* were detected, which colonize a wide range of hosts, including humans and animals, both mammalian and non-mammalian. Some STs exhibit host specificity with variable geographic distribution. There is a high prevalence of ST1 and ST2 in America, ST1 and ST3 in Australia, Europe, and South Eastern Asia, and ST4 in Europe [8]. Humans are colonized mainly by ST1 through ST4, comprising over 90% of reports; however, depending on the regions
and countries, infection by ST5 through ST9 is also observed [8, 41]. To date, ST10 through ST17 have not been found in humans [11, 41], with the exception of research by Ramirez et al. [42] in 2016, who reported, for the first time, human infection with ST12. Gender differences in the prevalence of Blastocystis STs have been reported. In Sweden, for instance, ST3 was found to be more common in males than in females, while in females, ST4 was almost as common as ST3. However, the difference in the relative frequency of ST4 between men and women was statistically insignificant [43].

In the recent literature, researchers have been debating over the correlation between distinct Blastocystis subtypes and their pathogenic potential. Clark was the first to suggest that different subtypes with different pathological potentials may exist [43]. With respect to that fact, in 2000, Kaneda et al. [27] suggested that STs 1, 2, and 4 might be responsible for gastrointestinal symptoms. In 2012, Poirier et al. [44] indicated that ST7 is correlated with IBS. Puthia et al. [45] have shown that, in rat epithelial cells, ST4 can induce apoptosis in a contact-independent manner to increase epithelial permeability. ST7 likely uses hydrolases to attack host tissues for its nutrient supply [44]. In 2006, Yan et al. [46] demonstrated only ST1 in a group of symptomatic patients, which was later confirmed by El Safadi et al. [47] in 2013, demonstrating that ST1 was associated with an elevated pathogenicity. The pathogenicity of ST4 was also hypothesized by Stensvold et al. [48] in a short report in 2011. The explanations for pathogenicity may include intra-subtype differences in Blastocystis protease activity, variations in intestinal microbiota of the individual host, and a symbiotic role for viruses associated with Blastocystis, which can interact to mediate host colonization and Blastocystis virulence [49, 50]. Also, the presence of gut microbiota seems to be essential for the pathogenic expression of enteric protozoan such as Blastocystis. The hypothesis of protozoa axenization by some bacteria has been proposed [51]. The cysteine proteases produced by ST4 and ST7 were revealed to be able to cleave human IgA in vitro [52, 53], as a mechanism for parasite survival and colonization in the gut, immune evasion, virulence, and cell cycle regulation [53]. Enzymes can also modulate inflammatory IL-8 production, as well as cathepsin B activation [54], and are able to increase the permeability of intestinal epithelial cells [45, 55].

In contrast, several studies showed no distinct differences in STs between isolates from symptomatic and asymptomatic groups of individuals with gastrointestinal disorders [39]. In addition to unspecific gastrointestinal symptoms, an association between the parasite subtypes and certain cutaneous disorders have been observed [56–59], such as the presence of Blastocystis ST2 [57], ST3 especially the amoeboid form, or ST4 in patients with acute or chronic urticaria (CU) [56, 58, 60–62]. Oxidative stress is probably another reason why certain Blastocystis subtypes are more virulent. It is reported that Blastocystis infection correlates with a significant oxidative burst, leading to oxidative stress [63]. Some subtypes may induce higher concentrations of oxidative stress and precipitate skin reactions such as urticaria. A recent study showed that live Blastocystis parasites and whole cell lysate alone did not activate toll-like receptors in the human TLR reporter monocyte cell line, while live ST4-WR1 parasites inhibited the LPS-mediated NF-κB activation. In contrast, whole cell lysates of ST7-B and ST4-WR1 induced pleiotropic modulation of ligand-specific TLR-2 and TLR-4 activation, with a compounding effect of ST7-B on LPS-mediated NF-κB activation [63]. A higher caspase-like activity of Blastocystis spp. ST3 was found in isolates from individuals who had gastrointestinal symptoms [65].

The human gut microbiota: current knowledge

The human microbiota is made up of different microbial communities present in different parts of the human body, such as the skin, vagina, oro-nasal cavity, esophagus, and gastrointestinal (GI) tract [66]. The human body is composed of about 10^{13} cells [67]. There are about ten times this number of microbial cells associated with the healthy human body [67]. These microbes interact with their host and have an impact on human health. The human GI microbiota is mostly concentrated in the colon and is made up of a majority of bacteria, a few archaea, known as the microbiome, viruses (the virome), fungi, and other uni- and multicellular eukaryotes, called protozoids and helminths, respectively [5, 68]. Only 30% of the human GI microbiota have been characterized [69]. It is difficult to describe the actual meaning of “normal” or “healthy” human GI microbiota. A “core microbiota” has been established [70], but it remains unclear what the essential constituents are. A number of studies have emphasized that the distribution of specific microbial communities among individuals could be influenced by several factors, including the geographical origin, age, diet of the studied individual, gender [71], stress, smoking, GI infections, as well as antibiotic or probiotic uptake [70, 72–78]. It is believed that the highly evolved biofilm communities that are closely associated with the intestinal epithelium are biologically more relevant than planktonic microbes that exist in the lumen of the gut or associated with food residue [79]. Furthermore, fecal specimens may not accurately portray the mucosal microbiota [72, 80]. And, also, there are significant differences between the microbiota of the liquid fraction compared with that associated with the solid phase [79].

The gut microbiota is typically dominated by bacteria and specifically by members of the divisions Bacteroidetes and Firmicutes [81]. From stomach to colon, the bacterial biomass ranges from 10^{2–3} to 10^{11–12} cells/mL [82]. Ninety-five percent of them are anaerobic bacteria and at least 1000 different species have been listed to date [83]. The most frequently
detected in the human gut are the phyla of the Firmicutes, Bacteroidetes, Actinobacteria, Cyanobacteria, Fusobacteria, Proteobacteria, and Verrucomicrobia [84]. Knowledge concerning bacterial communities far outpaces that of the viral and eukaryotic communities [85]. The observed ratio of 7–10 viral-like particles per microbial cell in environmental [86] human samples [87] means that we could expect to find as many as $10^{15}$ phages in the body, with the gut having the highest abundance of viruses, $3 \times 10^{12}$ [88]. The diversity of the human virome is low. It is estimated that there are 1500 viral genotypes in a typical healthy, human virome [88].

Studies of the viral community in the human gut showed Caudovirales to be prevalent [89]: Siphoviridae, Myoviridae, Podoviridae, Microviridae [90, 91]. Eukaryotes that reside in the human gut are distributed across the eukaryotic tree and their relationship with the human host varies from parasitic to opportunistic to commensal to mutualistic [92]. It has been known that yeasts constitute part of the intestinal flora: Candida spp. (C. parapsilosis, C. albicans, C. glabrata, C. krusei, C. tropicalis) or Saccharomyces boulardii [92, 93]. Diverse eukaryotes inhabit the human gut, including protists and helminths [92]. Many species of protists are commensals and harmless, including Pentatrichomonas and Entamoeba dispar [94]. Interestingly, available data suggest that many common eukaryotic residents are commensals, but are, in some cases, associated with gastrointestinal disorders [5]. Good examples are Blastocystis sp. or Dientamoeba fragilis [5, 95]. Other representative protists that are part of the human gut eukaryome include: Enteromonas hominis, Retortamonas intestinalis, Chilomastix mesnili, Entamoeba hartmanni, Entamoeba nana, Entamoeba coli, Isospora belli, Iodamoeba buetschi and Encephalitozoon cuniculi [5]. Pathogenicity is certainly the role for some intestinal protists, such as Cryptosporidium spp., Entamoeba histolytica or Giardia intestinalis [92], as well as for some helminths, such as Ascaris lumbricoides and Strongyloides stercoralis [5].

The role of Blastocystis in the human gut: bad and good sites

Blastocystis was first described more than 100 years ago, but there are still many obscurities about its clinical significance. It may colonize the bowels and is commonly isolated in individuals with neither gastrointestinal complaints nor symptoms [19, 47]. However, Blastocystis was also identified as the only causative agent of gastrointestinal or dermatological symptoms, such as abdominal pain, diarrhea, nausea, vomiting, bloating, anorexia, or, less commonly, urticaria, intense itching [56, 57], or iron deficiency anemia [96–98].

As mentioned above, there can be several explanations for Blastocystis pathogenicity. It may depend on the Blastocystis subtype: different subtypes can excrete protease enzymes which are able to take part in the induction of virulence [49, 99, 100]. Most Blastocystis isolates found in stool samples are in cyst or vacuolar forms. The amoeboïd form is rarely seen, but is mostly associated with symptoms [3]. Therefore, amoeboïd forms of Blastocystis are probably pathogenic. A large number of the parasites in the intestine (>5 parasites per high-power field) are also connected with gastrointestinal symptoms [1]. Human gut microbiota composition and the immune system are also deciding agents in the pathogenicity and occurrence of the parasite. In immunocompromised individuals, such as those with HIV infection, the prevalence reaches 38% in developed countries [28], and an association with diarrhea is suggested. The nutritional status of an individual may be one of the most important risk factors for co-infection [3]. Children and the elderly are highly susceptible to Blastocystis infection [20, 31], whereas research interestingly showed that people aged 30–50 years old are mostly infected [33]. Blastocystis can also have beneficial effects stemming from its ability to modulate the host immune system. One mechanism of action is the stimulation of mucus production, via the cytokine IL-22, which alleviates symptoms of colitis, improving gut health [101]. Perhaps Blastocystis is more common in healthy people because it helps maintain a healthy mucus layer in the intestine, either directly or through interactions with beneficial bacteria or the immune system [5]. Blastocystis have been shown to be more prevalent in patients suffering from IBS [18, 102–106]. A 2014 study by Nourrisson et al. [107] suggests that Blastocystis may be used as an indicator of microbiota changes; a lower abundance of Bifidobacterium spp. and Faecalibacterium prausnitzii were reported to have protective and anti-inflammatory effects, which could lead to intestinal dysbiosis and IBS. Nagel et al. [108] confirmed these results in 2016. On the other hand, in 2016, Audebert et al. [109] suggested that colonization by Blastocystis could be associated with a healthy gut microbiota. Their study showed a higher bacterial diversity in Blastocystis-colonized patients compared to that identified in Blastocystis-free individuals. In Blastocystis-colonized patients, there was a higher abundance of the Clostridia class and Ruminococcaceae and Prevotellaceae families, while Enterobacteriaceae were enriched in Blastocystis-free patients. The most recent results of the latest studies leave the pathogenicity of Blastocystis still unclear and this is similar to the chicken and egg question: which came first? It is still a mystery. Is Blastocystis an agent of the gut dysbiosis and changing the microbiotic diversity, or are the metabolic dysfunctions and changes in the content of microbiota the reason for the higher colonization by Blastocystis? There is a possibility that some species of bacteria are triggering the protease activity of Blastocystis, which causes the gastrointestinal symptoms. It may also depend on parasitic subtype. To address this, further studies in humans are required [109].
The influence of different diets on Blastocystis as compared to antibiotic treatment

Although many Blastocystis infections remain asymptomatic, recent data suggest that it is a frequent cause of gastrointestinal symptoms in children and adults [110]. Many parasitologists insist that, when Blastocystis organisms are present in large numbers in stool examination, even without the presence of any other known bacterial, viral, or parasitic infection, treatment should be proposed [110, 111]. Therapy should be limited to patients with relentless symptoms and a complete negative workup for alternative etiologies. Several drugs have been used against Blastocystis infection, the most common still being metronidazole (MTZ), as the first-line treatment, followed by nitazoxanide (NTZ), trimethoprim-sulfamethoxazole (TMP-SMX), ketoconazole, and tinidazole as secondary treatments. Studies have shown that, while MTZ demonstrates effectiveness in some individuals [112, 113], it has also been shown to exhibit side effects and resistance in others [114, 115]. Most probably, it depends on the Blastocystis subtypes. Girish et al. [116], in 2015, reported that STs 1, 3, and 5 are susceptible to MTZ, but resistant to ketoconazole, even when high doses were administrated. ST1 is also resistant to TMP-SMX in lower doses, and ST3 to NTZ in lower doses [116]. Studies have shown STs 4 and 7 to be resistant to MTZ [117]. This drug can cause undesirable side effects and changes in the gut microbiota. Moreover, failures in treatment are frequently reported [117–122]. Additionally, potential carcinogenic, teratogenic, and embryotoxic effects of metronidazole have been reported [123]. Therefore, there is a need to develop safe and alternative antimicrobial agents, such as the use of medicinal plants, spices, specific vegetables, or yeasts.

The number of trials, in vitro and in vivo, in which the anti-Blastocystis efficacies of some local plants are assessed have been on the rise lately [124]. Plants were chosen for their antimicrobial activity and chemical composition. Garlic (Allium sativum) contains a wide range of the thiosulfonates (e.g., allicin), which are responsible for the antibacterial activity [125] related to the inhibition of enzymes, including thiol in microorganisms [126, 127]. Moreover, allicin in the garlic acts by totally inhibiting RNA synthesis and partially inhibiting DNA and protein synthesis of the parasites [128]. Additionally, hexahydrocurcumin, a constituent isolated from ginger (Zingiber officinale), might be effective in killing the parasites [129]. Yakoob et al. [130] in 2011 and Abdel-Hafeez et al. [131] in 2015 proved activity against Blastocystis with garlic extract in vitro as compared to the antimicrobial drugs MTZ and NTZ, respectively. Interestingly, they also tested the antiparasitic activity of ginger and had differing results. As Yakoobs and colleagues [130] showed in their study, Blastocystis STs 1 and 3 were not sensitive to ginger, black pepper, or cumin when compared to garlic and MTZ. According to the study of Abdel-Hafeez et al. [131], ginger has the greatest effect on Blastocystis clinical isolates, but onion (Allium cepa) or turmeric (Curcuma longa) do not [131, 132]. Moreover, garlic and ginger decrease malondialdehyde (MDA) production significantly. The allicin contained in garlic acts as an antioxidant by retrieving reactive oxygen species (ROS), preventing lipid oxidation and production of pro-inflammatory messengers [133]. Additionally, gingerol contained in ginger inhibits the ascorbate/ferrous complex-induced lipid peroxidation [134]. Dugasani et al. [135], in 2010, reported that gingerols and shogaols are the most bioactive compounds of ginger. Both garlic and ginger seem to be strong antioxidants inhibiting nitric oxide (NO) production [131, 135]. Intestinal NO increases upon Blastocystis infection as a host defense mechanism of epithelial cells against parasites [117, 131]. Mirza et al. [117], in 2011, suggested that Blastocystis is susceptible to NO. Nitric oxide is important in homeostasis and host defense; however, it may also lead to cellular damage and gut barrier failure, as well as having been involved in the pathogenesis of many inflammatory and autoimmune diseases [136, 137]. Garlic and ginger treatments significantly downregulated NO intestinal release [131]. This may be caused by a decrease in Blastocystis loads in the intestine. Downregulation of MDA and NO are important mechanisms of garlic- and ginger-induced antiparasitic effects.

El Deeb et al. [138], in 2012, proved an inhibitory effect of Ferula asafoetida (in both powder and oil form) on Blastocystis ST3. Furthermore, asafoetida exerted a detrimental effect on Blastocystis morphology, which was especially obvious at higher concentrations. The viable vacuolar forms which were typically seen before incubation with either powder or oil were replaced by more granular forms, which lost viability over time and showed a shriveled appearance [138]. Asafoetida consists principally of volatile oil (4–20%) with isobutyl propanyl disulfide (C8H16S2), resin (40–60%) with ester of asaresinotannol and free ferulic acid, and gum (~25%) with caffeic acid cinnamyl ester showing moderate activity for inhibiting LPS-induced nitric oxide production in murine macrophage RAW264.7 cells [139]. Blastocystis ST3 is also sensitive to Tongkat Ali (Eurycoma longifolia), as Girish and colleagues proved in a study in 2015 [116]. Most likely, four compounds are responsible for antiparasitic activity: 3,4-dihydrochapparinone, laurylcoactone B, β-carboline-1-propionic acid, and canthin-6-one. These compounds have previously been proven to possess therapeutic properties [140, 141]. Recently, there have been many reports which have
shown the inhibitory effect of herbal extracts and spices on Blastocystis. Vital and Rivera [142], in 2009, proved that ethanol extracts of leaves of Chromolaena odorata and ethyl acetate extracts of stem bark of Uncaria perrottetii inhibited Blastocystis growth and decreased cell counts at 0.5 and 1.0% concentrations, respectively. Furthermore, Özbílgín et al. [143], in a 2013 study, demonstrated that the methanol extract of Achillea millefolium gave promising results and could be used as an antibiotic in the future, especially against Blastocystis STs 1, 2, and 3. Also, El Wakil [144], in 2007, showed that an aqueous extract of Nigella sativa significantly inhibits the growth of Blastocystis isolates. In addition, some medicinal plants from Ghana and Thailand showed high activity against Blastocystis [145, 146]. Similarly, supplementation with 600 mg emulsified oil of Mediterranean oregano (Origanum vulgare) daily lead to the complete disappearance of Blastocystis [147].

It is also suggested to use Saccharomyces boulardii to cure Blastocystis infection [111]. Commensal yeasts act as a regulator of homeostasis in the gut through preventing the colonization of pathogenic agents on intestinal mucosa and augmenting the local immune response [148]. In a placebo-controlled study, it was found to be more effective against Blastocystis when compared to metronidazole [111].

Conclusions

Blastocystis sp. is a parasite which does not need to be cured with the antibiotics that cause side effects, such as metronidazole (MTZ). Mainly, the choice of eradication depends on the Blastocystis subtype, geographic region of occurrence, pathogenicity, immune system of the host, human gut microbiota, or chronic diseases, such as diabetes. Natural herbs, vegetables, or spices as an alternative for blastocystosis treatment not only reduce drug resistance, but also their side effects and the cost of treatment, especially in developing countries. Special diets are effective mainly by inhibiting parasitic enzyme activity, RNA, DNA, and protein synthesis, and, also, nitric oxide (NO) production. Moreover, commensal yeasts and bacteria prevent the colonization of pathogenic agents on intestinal mucosa and augment the local immune response. Certain species of beneficial microorganisms can have a negative influence on parasites by producing molecules that trigger the immune system, but they may also cause protease activity in Blastocystis, leading to symptoms of infection. Further investigation needs to be done to identify the organic compounds causing Blastocystis eradication. Research should address if the treatment directly affects Blastocystis or if it acts by destroying the bacterial flora necessary for its development, or both. We would like to suggest for future research the determination of whether Blastocystis is an agent changing the human gut microbiota or the opposite; does the commensal microbiota help the parasite to colonize the gastrointestinal tract? These questions and many others still remain unclear.

Compliance with ethical standards

Funding None.

Conflict of interest None.

Ethical approval Not necessary; this is a review.

Informed consent Not necessary; this is a review.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Tan KS (2008) New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev 21:639–665. doi:10.1128/CMR.00022-08
2. Moosavi A, Haghighi A, Mojarad EN, Zayeri F, Alebouyeh M, Khazan H, Kazemi B, Zali MR (2012) Genetic variability of Blastocystis sp. isolated from symptomatic and asymptomatic individuals in Iran. Parasitol Res 111:2311–2315. doi:10.1007/s00436-012-3085-5
3. Basak S, Rajurkar MN, Mallick SK (2014) Detection of Blastocystis hominis: a controversial human pathogen. Parasitol Res 113:261–265. doi:10.1007/s00436-013-3652-4
4. Wawrzyniak I, Poirier P, Viscogliosi E, Dionigia M, Texier C, Delbae F, Alaoui HE (2013) Blastocystis, an unrecognized parasite: an overview of pathogenesis and diagnosis. Ther Adv Infect Dis 1:167–178. doi:10.1177/2049936113504754
5. Lukeš J, Stensvold CR, Jirků-Pomajbíková K, Wegener Parfrey L (2015) Are human intestinal eukaryotes beneficial or commensals? PLoS Pathog 11(8), e1005039. doi: 10.1371/journal.ppat.1005039
6. Silberman JD, Sogin ML, Leipe DD, Clark CG (1996) Human parasite finds taxonomic home. Nature 380:398. doi:10.1038/380398a0
7. Irkov OA, Antokhin AI, Romanov YA (2009) Study of the dynamics of Blastocystis hominis reproduction in vitro. Bull Exp Biol Med 148:99–102. doi:10.1134/s05170924090517
8. Stensvold CR, Suresh GK, Tan KS, Thompson RC, Traub RJ, Viscogliosi E, Yoshikawa H, Clark CG (2007) Terminology for Blastocystis subtypes—a consensus. Trends Parasitol 23:93–96. doi:10.1016/j.pt.2007.01.004
9. Parija SC, Jeremiah S (2013) Blastocystis: taxonomy, biology and virulence. Trop Parasitol 3:17–25. doi:10.4103/2229-5070.113894
10. Alfellani MA, Taner-Mulla D, Jacob AS, Imeede CA, Yoshikawa H, Stensvold CR, Clark CG (2013) Genetic diversity of Blastocystis in livestock and zoo animals. Prost 164:497–509. doi:10.1016/j.prote.2013.05.003
11. Forsell J, Granlund M, Stensvold CR, Clark CG, Evengård B (2012) Subtype analysis of Blastocystis isolates in Swedish patients. Eur J Clin Microbiol Infect Dis 31:1689–1696. doi:10.1007/s10096-011-1416-6

12. Souppart L, Sanciu G, Cian A, Wawrzyniak I, Delbac F, Capron M, Dei-Cas E, Boorom K, Delhaes L, Viscoligosi E (2009) Molecular epidemiology of human Blastocystis isolates in France. Parasitol Res 105:413–421. doi:10.1007/s00436-009-1398-9

13. Noël C, Duflernez C, Gerbod D, Edgcombe VP, Delgardo-Viscoligosi P, Ho LC, Singh M, Wintjens R, Sogin ML, Capron M, Pierce R, Zentner L, Viscoligosi E (2005) Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. J Clin Microbiol 43:348–355. doi:10.1128/JCM.43.2.348-355.2005

14. Yoshikawa H, Wu Z, Pandey K, Pandey BD, Sherchand JB, Yanagi T, Kanbara H (2009) Molecular characterization of Blastocystis isolates from children and rhesus monkeys in Kathmandu, Nepal. Vet Parasitol 160:295–300. doi:10.1016/j.vetpar.2008.11.029

15. Abe N (2004) Molecular and phylogenetic analysis of Blastocystis isolates from various hosts. Vet Parasitol 120:235–242. doi:10.1016/j.vetpar.2004.01.003

16. Rivera WL (2008) Phylogenetic analysis of Blastocystis isolates from animal and human hosts in the Philippines. Vet Parasitol 156:178–182. doi:10.1016/j.vetpar.2008.06.001

17. Roberts T, Stark D, Harkness J, Ellis J (2014) Update on the pathogenic potential and treatment options for Blastocystis sp. Gut Pathog 6:17. doi:10.1186/1757-4749-6-17

18. Yakoob J, Jafri W, Beg MA, Abbas Z, Naz S, Islam M, Khan R (2010) Irritable bowel syndrome: is it associated with genotypes of Blastocystis hominis? Parasitol Res 106:1033–1038. doi:10.1007/s00436-010-1761-x

19. Bálint A, Dóczi I, Bereczki L, Gyulai R, Szabó M, Farkas K, Urbán E, Nagy F, Szepes Z, Wittmann T, Molnár T (2014) Do Blastocystis hominis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. J Clin Microbiol 52:1107–1110. doi:10.1128/JCM.03261-13

20. Tan TC, Suresh KG (2006) Predominance of amoeboid forms of Blastocystis sp. in isolates from symptomatic patients. Parazitologiya 38:119–123. doi:10.1016/S0166-2448(06)812. doi:10.1016/0020-7519(91)90149-2

21. El-Safadi D, Gazyeh L, Meloni D, Cian A, Poirier P, Wawrzyniak I, Delbac F, Dabbousi F, Delhaes L, Seck M, Hamze M, Riveau G, Viscoligosi E (2014) Children of Senegal River Basin show the highest prevalence of Blastocystis sp. ever observed worldwide. BMC Infect Dis 14:164–174. doi:10.1186/1471-2334-14-164

22. Doyle PW, Helgason MM, Mathias RG, Proctor EM (1990) Epidemiology and pathogenicity of Blastocystis hominis. J Clin Microbiol 28:116–121

23. Lu CT, Sung YJ (2009) Epidemiology of Blastocystis hominis and other intestinal parasites among the immigrant population in northeastern Taiwan by routine physical examination for residence approval. J Microbiol Immunol Infect 42:505–509

24. Zaglool DAM, Khodari YAW, Farooq MU (2012) Blastocystis hominis and allergic skin diseases; a single centre experience. J Health Sci 2:66–69. doi:10.17532/jhsci.2012.66

25. Tan TC, Suresh KG (2006) Predominance of amoeboid forms of Blastocystis sp. in isolates from symptomatic patients. Parazitologiya 38:119–123. doi:10.1016/S0166-2448(06)812. doi:10.1016/0020-7519(91)90149-2

26. Elsharif M, Yunis MS, El Fakahany AF, Nagaty IM, Nagib MM (2015) Laboratory diagnosis of Blastocystis spp. in diarrheic patients. Trop Parasitol 5(1):36–41. doi:10.4103/2229-5070.149919

27. Abaza SMM (2000) Blastocystis hominis: update. Review article

28. Stenzel DJ, Boreham PF, McDougall R (1991) Ultrastructure of Blastocystis hominis in human stool samples. Int J Parasitol 21:807–812. doi:10.1016/0020-7519(91)90149-2

29. Yoshikawa H, Wu Z, Kimata I, Iseki M, Ali IK, Hossain MB, Zhang L (2007) Molecular epidemiology of human Blastocystis spp. in diarrheic patients. J Infect Dev Ctries 1:76–81. doi:10.1016/j.parint.2006.11.003

30. El-Safadi D, Gazyeh L, Meloni D, Cian A, Poirier P, Wawrzyniak I, Delbac F, Dabbousi F, Delhaes L, Seck M, Hamze M, Riveau G, Viscoligosi E (2014) Children of Senegal River Basin show the highest prevalence of Blastocystis sp. ever observed worldwide. BMC Infect Dis 14:164–174. doi:10.1186/1471-2334-14-164

31. Stenzel DJ, Boreham PF, McDougall R (1991) Ultrastructure of Blastocystis hominis in human stool samples. Int J Parasitol 21:807–812. doi:10.1016/0020-7519(91)90149-2

32. Scanlan PD, Stensvold CR, Rajilić-Stojanović M, Heilig HG, De Vos WM, O’Toole PW, Cotter PD (2014) The microbial eukaryote Blastocystis is a prevalent and diverse member of the healthy human gut microbiota. FEMS Microbiol Ecol 90:326–330. doi:10.1111/1574-6941.12396

33. Alfellani MA, Stensvold CR, Vidal-Lapiedra A, Onuoha ES, Fagbenro-Beyioku AF, Clark CG (2013) Variable geographic distribution of Blastocystis subtypes and its potential implications. Acta Trop 121:16–18. doi:10.1016/j.actatropica.2012.12.011

34. Stensvold CR (2013) Blastocystis: genetic diversity and molecular methods for diagnosis and epidemiology. Trop Parasitol 3:26–34. doi:10.4103/2229-5070.113896

35. Li LH, Zhou XN, Du ZW, Wang XZ, Wang LB, Jiang JY, Yoshikawa H, Steinnmann P, Utzinger J, Wu Z, Chen JX, Chen SH, Zhang L (2007) Molecular epidemiology of human Blastocystis in a village in Yunnan province, China. Parasitol Int 56:281–286. doi:10.1016/j.parint.2007.06.001

36. Chen TY, Chan CC, Chen HP, Fung CP, Lin CP, Chen WL, Liu CY (2003) Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. Am J Trop Med Hyg 69:213–216

37. Raš-Norynská M, Bialkowska J, Sokół R, Piskorz-Ogórek K (2011) Parasitological stool examination from children without the typical symptoms of parasitic disease. Przegl Epidemiol 65:599–603
97. El Deeb HK, Khodere S (2013) Blastocystis spp.: frequency and subtype distribution in iron deficiency anemia versus non-anemic subjects from Egypt. J Parasitol 99(4):599–602. doi:10.1645/12-80.1
98. Scanlan PD, Stensvold CR (2013) Blastocystis: getting to grips with our guileful guest. Trends Parasitol 29(11):523–529. doi:10.1016/j.pt.2013.08.006
99. Kurt Ö, Dogman AI, Tanyükel M (2016) Eradication of Blastocystis in humans: Really necessary for all? Parasitol Int 65:797–801. doi:10.1016/j.parint.2016.01.010
100. Leung JM, Davenport M, Wollf MJ, Wiens KE, Abidi WM, Poles MA, Cho I, Ullman T, Mayer L, Loke P (2014) IL-22-producing C4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 7:124–133. doi:10.1038/mi.2013.31
101. Giacometti A, Cirioni O, Fiorentini A, Fortuna M, Scalise G (1999) Irritable bowel syndrome in patients with Blastocystis hominis infection. Eur J Clin Microbiol Infect Dis 18:436–439
102. Yakooj J, Jafri W, Jafri N, Khan R, Islam M, Beg MA, Zaman V (2004) Irribale bowel syndrome: in search of an etiology: role of Blastocystis hominis. Am J Trop Med Hyg 70:383–385
103. Yakooj J, Jafri W, Beg MA, Abbas Z, Naz S, Islam M, Khan R (2010) Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 107:679–684. doi:10.1007/s00436-010-1918-7
104. Dogman-AI F, Kustimur S, Yoshikawa H, Tuncer C, Simske Z, Tanyükel M, Araz E, Boorom K (2009) Blastocystis subtypes in irritable bowel syndrome and inflammatory bowel disease in Ankara, Turkey. Mem Inst Oswaldo Cruz 104:724–727. doi:10.1590/S0074-02762009000500011
105. Jimenez-Gonzalez DE, Martinez-Flores WA, Reyes-Gordillo J, Ramirez-Miranda ME, Arroyo-Escalante S, Romero-Valdivinos M, Stark D, Souza-Saldivar V, Martinez-Hernandez F, Flisser A, Olivo-Diaz A, Maravilla P (2012) Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population. Parasitol Res 110:1269–1275. doi:10.1007/s00436-011-2626-7
106. Nourrisson C, Scanzi J, Pereira B, NkoudMongc C, Wawrzyniak J, Cian A, Viscoiglosi E, Livrelli V, Delbac F, Poirier M, Poirier P (2014) Blastocystis is associated with decrease of fecal microbiota protective bacteria: comparative analysis between patients with irritable bowel syndrome and control subjects. PLoS One 9(11), e111868. doi:10.1371/journal.pone.0111868
107. Nagel R, Traub RJ, Allicko RJN, Kwan MMS, Bielefeldt-Ohmann H (2016) Comparison of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel syndrome patients. Microbiome 4(1):47. doi:10.1186/s40168-016-0191-0
108. Audebert C, Even G, Cian A, Blastocystis Investigation Group, Loywick A, Merlin S, Viscoiglosi E, Chabé M (2016) Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. Sci Rep 6, 25255. doi:10.1038/srep25255
109. Tan KS, Singh M, Yap EH (2002) Recent advances in Blastocystis hominis research: hot spots in terra incognita. Int J Parasitol 32:789–804. doi:10.1016/S0166-5830(02)00292-9
110. Ninileyi EC, Eren M, Dogan N, Reynaynhogu S, Yargic ZA, Vandenplas Y (2011) Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res 108:541–545. doi:10.1007/s00436-010-1995-4
111. Lucia JF, Aguilar C, Betran A (2007) Blastocystis hominis colitis in a haemophilic patient as a cause of lower gastrointestinal bleeding. Haemophilia 13(2):224–225. doi:10.1111/j.1365-2516.2006.01434.x
112. Moghaddam DD, Ghadrian E, Azami M (2005) Blastocystis hominis and the evaluation of efficacy of metronidazole and...
trime thoprim/sulfamethoxazole. Parasitol Res 194(4): 273–275. doi:10.1007/s00436-005-1363-1

114. Johnson PJ (1993) Metronidazole and drug resistance. Parasitol Today 9:183–186. doi:10.1016/0169-4758(93)90143-4

115. Voolmann T, Boreham PFL (1993) Metronidazole resistant Trichomonas vaginalis in Brisbane. Med J Aust 159:490

116. Girish S, Kumar S, Aminudin N (2015) Long-acting novel anti-inflammatory drug (Eurycoma longifolia): a possible therapeutic candidate against Blastocystis spp. Parasit Vectors 8:332. doi:10.1186/s13071-015-0942-y

117. Mirza H, Wu Z, Kidwai F, Tan KSW (2011) A metronidazole-resistant isolate of Blastocystis spp. is susceptible to nitric oxide and downregulates intestinal epithelial inducible nitric oxide synthase by a novel parasite survival mechanism. Infect Immun 79(12):5019–5026. doi:10.1128/IAI.05632-11

118. Lemée V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, Ballet JJ, Favennee L (2000) Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J Antimicrob Chemother 46:819–821. doi:10.1093/jac/46.5.814

119. Haresh K, Suresh K, Khairul Anas A, Saminathan S (1999) Isolate resistance of Blastocystis hominis to metronidazole. Trop Med Int Health 4:274−277. doi:10.1046/j.1365-3156.1999.00398.x

120. Zaman V, Zaki M (1996) Resistance of Blastocystis hominis cysts to metronidazole. Trop Med Int Health 1:677−678. doi:10.1111/j.1365-3156.1996.tb00094.x

121. Stensvold CR, Smith HV, Olsen KEP, Traub RJ (2010) Eradication of Blastocystis carriage with antimalarials: reality or delusion? J Clin Gastroenterol 44(2):85−90. doi:10.1097/MGC.0b013e3181b860a

122. Sekar U, Shanthi M (2013) Blastocystis consensus: concepts of treatment and controversies. Trop Parasitol 3:35−39. doi:10.4103/2229-5070.113901

123. Roe FJ (1983) Toxicologic evaluation of metronidazole with paracetamol and aspirin. J Toxicol Cutan Ocul Toxcol 3(7):511−518. doi:10.1016/0169-4758(93)90143-4

124. Gonçagul G, Ayaz E (2010) Antimicrobial effect of garlic (Allium sativum) and ginger (Zingiber officinale) extracts on experimentally infected mice with Blastocystis spp. Parasitol Res 110(9):3439−3444. doi:10.1007/s00436-015-4569-x

125. Abdel-Hafeez EH, Ahmad AK, Abdellatif MZ, Kamal AM, Mohamed RM (2015) In vitro effect of some Egyptian herbal extracts against Blastocystis hominis. J Egypt Soc Parasitol 45(1):93−100. doi:10.12816/00010854

126. Ahmed RS, Seth V, Banerjee BD (2001) Influence of dietary ginger (Zingiber officinale Rosc) on antioxidant defense system in rats: comparison with ascorbic acid. Indian J Exp Biol 38:604−606

127. Dugasani S, Pichika MR, Nadarajah VD, Balijepalli MK, Tandra S, Korlakunta JN (2010) Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol 127:515−520. doi:10.1016/j.jep.2009.10.004

128. Potoka DA, Nadler EP, Upperman JS, Ford HR (2002) Role of nitric oxide and peroxynitrite in gut barrier failure. World J Surg 26:806−811. doi:10.1007/s00268-002-4056-2

129. Tan KSW, Hew K, Lim AJ, Bastow KF, Lee KH, Wu TS (2003) Cytotoxic and anti-malarial beta-carboline alkaloids from the roots of Eurycoma longifolia. J Nat Prod 66(10):1324−1327. doi:10.1021/jn020277n

130. Vital PG, Rivera WL (2009) Antimicrobial activity and cytotoxicity of Chromolaena odorata (L.) King and Robinson and Uncaria perrottetii (A. Rich) Menz. Extracis. J Med Plants Res 3(7):511−518

131. Reddy Y, Muruganandam A, Kalyani S, Kandadai K, Kuppusamy V (2010) Isolation and characterization of antimicrobial and antioxidant compounds from Chromolaena odorata. J Medicinal Plants Res 4(1):1−8. doi:10.5897/JMPR2010.0160

132. Costa LS, Gouveia M, Proctor C (2015) Antitumor activity and inhibition of growth of the intestinal protozoa parasite: Blastocystis spp. isolates. J Ethnopharmacol 174:569−576. doi:10.1016/j.jep.2015.03.006

133. Sawangjaroen N, Sawangjaroen K (2005) The effects of extracts of Euphorbia hirta, Zingiber officinale, and Allium sativum on Blastocystis hominis isolates. J Egypt Soc Parasitol 35:711−716

134. Vandenplas Y, Huys G, Daube G (2015) Probiotics: an update. J Pediatr (Rio J) 91(1):6−21. doi:10.1016/j.jped.2014.08.005